Quality Systems – Page 40

AE reporting non-compliance during audit response – preventing repeat PV findings

“`html Addressing AE Reporting Non-Compliance During Audit Responses: A Structured Investigation During regulatory audits, findings related to adverse event (AE) reporting can lead to serious compliance issues for pharmaceutical companies.…

Supplier qualification gap during supplier change – regulatory risk analysis and mitigation

Identifying and Addressing Supplier Qualification Gaps During Change: A Comprehensive Investigation In pharmaceutical manufacturing, the supplier qualification process is critical to ensuring quality, compliance, and regulatory adherence. Amidst supplier changes,…

Risk management plan gaps during benefit–risk assessment – inspection questioning scenarios

Identifying and Addressing Risk Management Plan Gaps in Benefit–Risk Assessment In the pharmaceutical industry, effective risk management is essential to ensure drug safety and regulatory compliance. Yet, organizations frequently encounter…

Supplier qualification gap during market launch – documentation gaps regulators question

Identifying and Addressing Supplier Qualification Gaps During Market Launch In the fast-paced environment of pharmaceutical manufacturing, the launch of a new product often unveils various challenges, particularly in the realm…

AE reporting non-compliance during inspection – how to strengthen benefit–risk documentation

Improving Compliance in AE Reporting During Inspections: A Thorough Investigation Adverse Event (AE) reporting non-compliance during regulatory inspections represents a significant challenge for pharmaceutical professionals, particularly within clinical and pharmacovigilance…

Supplier qualification gap during supplier change – inspection evidence expectations

Addressing Gaps in Supplier Qualification During Transitions: Key Investigation Strategies In the constantly evolving landscape of pharmaceutical manufacturing, managing supplier changes presents a significant challenge. A lack of robust supplier…

Periodic report inconsistencies during benefit–risk assessment – CAPA for PV system weaknesses

Addressing Inconsistencies in Periodic Reports During Benefit–Risk Assessment for CAPA in Pharmacovigilance Systems In the realm of pharmacovigilance, maintaining data integrity and compliance during benefit-risk assessments is paramount. Periodic report…

Supplier qualification gap during development – documentation gaps regulators question

Addressing Supplier Qualification Gaps During Development: A Step-by-Step Investigation In the pharmaceutical industry, ensuring that suppliers meet stringent regulatory requirements is paramount. However, gaps often emerge during the development stage,…

Literature surveillance failure during inspection – how to strengthen benefit–risk documentation

How to Address Literature Surveillance Failures During Inspections: Strengthening Benefit–Risk Documentation In the pharmaceutical industry, ensuring the reliability of benefit-risk assessment documentation is crucial for regulatory compliance. Failures in literature…

Supplier qualification gap during scale-up – regulatory risk analysis and mitigation

Assessing Supplier Qualification Gaps During Scale-Up: A Regulatory Audit Approach In the pharmaceutical industry, scale-up processes are critical as they transition product development from small-scale trials to full-scale production. However,…

Literature surveillance failure during benefit–risk assessment – regulatory enforcement risk and mitigation

“`html Understanding Literature Surveillance Failures in Benefit–Risk Assessments In the pharmaceutical industry, literature surveillance is a crucial component of benefit–risk assessments, helping ensure the safe use of medications. However, failures…

Container closure integrity risk during scale-up – documentation gaps regulators question

Evaluating Risks of Container Closure Integrity During Scale-Up: Closing Documentation Gaps In the pharmaceutical manufacturing landscape, the integrity of container closures during product scale-up is of paramount importance. A breach…